Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KYNBthis companyKyntra Bio, Inc.	$3.88	0.19×	-1.18×	5.51×	0.22×	171.2%	91.4%	-712.7%	2848.6%	-610.7%	-50.7%	-13.6%	0×	0.83×	-5.24×	3.39×	0.0%	5	-25.88	3	B
ALGSAligos Therapeutics, Inc.	$4.54	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
ATNMActinium Pharmaceuticals, Inc.	$1.57	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
CELUCelularity Inc.	$0.73	-0.31×	-0.75×	1.07×	-0.81×	-1859.9%	24.4%	-230.9%	-345.4%	241.0%	-151.1%	-46.6%	-1.07×	-0.45×	-9.08×	0.15×	20.8%	3	-16.24	2	C
OKUROnKure Therapeutics, Inc.	$2.78	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
PDSBPDS Biotechnology Corporation	$1.12	-1.04×	3.86×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	1.83×	0.32×	-5.91×	2.98×	0.0%	2	-44.34	2	C
Peer median	—	-1.04×	1.72×	1.07×	-0.81×	-89.5%	24.4%	-230.9%	-345.4%	-105.9%	-116.5%	-77.7%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	—